Skip to main content
SpringerLink
Log in

The Current Role of Clevidipine in the Management of Hypertension

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Acute hypertension, which may damage blood vessels, causes irreversible organ damage to the vasculature, central nervous system, kidney, and heart. Clevidipine, the first third-generation calcium channel antagonist approved by the Food and Drug Administration (FDA) in the past 20 years, is an ultra-short-acting calcium channel blocker that inhibits L-type calcium channels with high clearance and low distribution, can be rapidly metabolized into the corresponding inactive acid, and is rapidly hydrolyzed into inactive metabolites by esterase in arterial blood. Clevidipine is the same as nicardipine in that the main physiological effect is vasodilation and the main target is the arterial system, which has a limited effect on capacitor vessels. Unlike nitroglycerin, clevidipine has a limited effect on preload. In contrast to other direct-acting vasodilators, clevidipine has an ultra-short half-life due to metabolism by nonspecific blood and tissue esterases. Clevidipine trials conducted in adult populations have proven that it can rapidly control blood pressure in cardiac surgery situations and that adverse reactions to clevidipine are similar to those with other antihypertensive agents. In recent years, clinical trials have shown that clevidipine has excellent blood pressure-lowering capability in patients with acute neurological injury (hemorrhage, stroke, and subarachnoid and acute intracerebral hemorrhage), those  undergoing coronary artery bypass graft or spinal surgery, and in those with cerebral aneurysm/pheochromocytoma, acute heart failure, acute aortic syndromes, or renal insufficiency with severe hypertension, and it is equivalent to commonly used blood pressure-lowering medicines such as nicardipine or nitroglycerin. However, there is a lack of large-scale clinical trial data on the efficacy and safety of clevidipine in children during the perioperative period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rivera A, Montoya E, Varon J. Intravenous clevidipine for management of hypertension. Integr Blood Press Control. 2010;3:105–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Borrell-Vega J, Uribe AA, Palettas M, Bergese SD. Clevidipine use after first-line treatment failure for perioperative hypertension in neurosurgical patients: a single-center experience. Medicine (Baltimore). 2020;99(1):e8541.

    Google Scholar 

  3. Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014;74(16):1947–60.

    CAS  PubMed  Google Scholar 

  4. Alviar CL, Gutierrez A, Cho L, et al. Clevidipine as a therapeutic and cost-effective alternative to sodium nitroprusside in patients with acute aortic syndromes. Eur Heart J Acute Cardiovasc Care. 2020;9(3_suppl):S5–12.

    PubMed  Google Scholar 

  5. Kenyon KW. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension. Ann Pharmacother. 2009;43(7):1258–65.

    CAS  PubMed  Google Scholar 

  6. Prlesi L, Cheng-Lai A. Clevidipine: a novel ultra-short-acting calcium antagonist. Cardiol Rev. 2009;17(3):147–52.

    PubMed  Google Scholar 

  7. Ericsson H, Tholander B, Björkman JA, Nordlander M, Regårdh CG. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999;27(5):558–64.

    CAS  PubMed  Google Scholar 

  8. Ndefo UA, Erowele GI, Ebiasah R, Green W. Clevidipine: a new intravenous option for the management of acute hypertension. Am J Health Syst Pharm. 2010;67(5):351–60.

    CAS  PubMed  Google Scholar 

  9. Ericsson H, Fakt C, Höglund L, Jolin-Mellgård A, Nordlander M, Sunzel M, Regårdh CG. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 1999;55(1):61–7.

    CAS  PubMed  Google Scholar 

  10. Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8(1):29–37.

    CAS  PubMed  Google Scholar 

  11. Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård A, Nordlander M, Regårdh CG. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92(4):993–1001.

    CAS  PubMed  Google Scholar 

  12. Smith WB, Marbury TC, Komjathy SF, Sumeray MS, Williams GC, Hu MY, Mould DR. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension. Eur J Clin Pharmacol. 2012;68(10):1385–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ericsson H, Fakt C, Jolin-Mellgård A, Nordlander M, Sohtell L, Sunzel M, Regårdh CG. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999;47(5):531–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhang Y, Zhao S, Zhou H, Ding L. Development and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1161:122448.

    CAS  PubMed  Google Scholar 

  15. Wang Y, et al. Pharmacokinetics and tissue distribution study of clevidipine and its primary metabolite H152/81 in rats. Biomed Chromatogr. 2018;32(2):e4048.

    Google Scholar 

  16. Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010;30(5):515–28.

    CAS  PubMed  Google Scholar 

  17. The Medicines Company. Cleviprex (clevidipine butyrate) package insert. Parsippany, NJ; 2008.

  18. Frank Peacock W, Varon J, Ebrahimi R, DunbarPollack LCVJRJ. Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis. Blood Press Suppl. 2011;1(Suppl 1):20–5.

    PubMed  Google Scholar 

  19. Brower KI, Murphy C, Arias-Morales CE, Rankin D, Palettas M, Bergese SD. Safety and efficacy of intravenous clevidipine for the perioperative control of acute hypertension in neurosurgical patients: a dose update. Clin Med Insights Ther. 2017. https://doi.org/10.1177/1179559X17712517.

    Article  Google Scholar 

  20. Segawa D, Sjöquist PO, Nordlander M, Wang QD, Gonon A, Rydén L. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur J Pharmacol. 1999;380(2–3):123–8.

    CAS  PubMed  Google Scholar 

  21. Lemkuil BP, Gierl BT, Patel PM, Pearn ML, Nguyen LC, Minokadeh A, Drummond JC. The Effect of clevidipine on cerebral blood flow velocity and carbon dioxide reactivity in human volunteers. J Neurosurg Anesthesiol. 2016;28(4):337–40.

    PubMed  Google Scholar 

  22. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002;24(4):301–13.

    CAS  PubMed  Google Scholar 

  23. Abdelgalel EF. Controlled hypotensive anesthesia for endoscopic endonasal repair of cerebrospinal fluid rhinorrhea: a comparison between clevidipine and esmolol: Randomized controlled study. Egypt J Anaesth. 2018;34(1):1–7.

    Google Scholar 

  24. Gradman AH, Vivas Y. New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker. Expert Opin Investig Drugs. 2007;16(9):1449–57.

    CAS  PubMed  Google Scholar 

  25. Nguyen HM, Ma K, Pham DQ. Clevidipine for the treatment of severe hypertension in adults. Clin Ther. 2010;32(1):11–23.

    CAS  PubMed  Google Scholar 

  26. Aronson S, Dyke CM, Stierer KA, Levy JH, Cheung AT, Lumb PD, Kereiakes DJ, Newman MF. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110–21.

    CAS  PubMed  Google Scholar 

  27. Aronson S. Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials. Expert Rev Cardiovasc Ther. 2009;7(5):465–72.

    CAS  PubMed  Google Scholar 

  28. Powroznyk AV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgård A, Latimer RD, Nordlander M, Feneck RO. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 2003;20(9):697–703.

    CAS  PubMed  Google Scholar 

  29. Espinosa A, Ripollés-Melchor J, Casans-Francés R, et al. Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11(3):e0150625.

    PubMed  PubMed Central  Google Scholar 

  30. Ulici A, Jancik J, Lam TS, Reidt S, Calcaterra D, Cole JB. Clevidipine versus sodium nitroprusside in acute aortic dissection: a retrospective chart review. Am J Emerg Med. 2017;35(10):1514–8.

    PubMed  Google Scholar 

  31. Noviawaty I, Uzun G, Qureshi AI. Drug evaluation of clevidipine for acute hypertension. Expert Opin Pharmacother. 2008;9(14):2519–29.

    CAS  PubMed  Google Scholar 

  32. Huraux C, Makita T, Szlam F, Nordlander M, Levy JH. The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997;85(5):1000–4.

    CAS  PubMed  Google Scholar 

  33. Pascual MJ, Sastre JA, Calvo JM. Intraoperative clevidipine use to manage an acute hypertensive episode in a patient with a simultaneous kidney-pancreatic transplant. J Clin Anesth. 2018;45:53–4.

    PubMed  Google Scholar 

  34. Levy JH, Mancao MY, Gitter R, Kereiakes DJ, Grigore AM, Aronson S, Newman MF. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105(4):918–25 (table of contents).

    CAS  PubMed  Google Scholar 

  35. Singla N, Warltier DC, Gandhi SD, Lumb PD, Sladen RN, Aronson S, Newman MF, Corwin HL, ESCAPE-2 Study Group. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59–67.

    CAS  PubMed  Google Scholar 

  36. Bekker A, Didehvar S, Kim S, et al. Efficacy of clevidipine in controlling perioperative hypertension in neurosurgical patients: initial single-center experience. J Neurosurg Anesthesiol. 2010;22(4):330–5.

    PubMed  Google Scholar 

  37. Freiberger NA, Tellor KB, Stevens AM. Comparison of clevidipine versus sodium nitroprusside for the treatment of postoperative hypertension in cardiac surgery patients. Hosp Pharm. 2016;51(6):461–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Wu M, Ryan KR, Rosenthal DN, Jahadi O, Moss J, Kwiatkowski DM. The use of clevidipine for hypertension in pediatric patients receiving mechanical circulatory support. Pediatr Crit Care Med. 2020;21(12):e1134–9.

    PubMed  Google Scholar 

  39. Pollack CV, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Peacock WF 4th. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):329–38.

    PubMed  Google Scholar 

  40. Barrett TW, Schriger DL, Pollack CV, Varon J, Garrison NA, Annals of Emergency Medicine Journal Club, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):339–40.

    PubMed  Google Scholar 

  41. Rosenfeldt Z, Conklen K, Jones B, Ferrill D, Deshpande M, Siddiqui FM. Comparison of nicardipine with clevidipine in the management of hypertension in acute cerebrovascular diseases. J Stroke Cerebrovasc Dis. 2018;27(8):2067–73.

    PubMed  Google Scholar 

  42. Allison TA, Bowman S, Gulbis B, Hartman H, Schepcoff S, Lee K. Comparison of clevidipine and nicardipine for acute blood pressure reduction in patients with stroke. J Intensive Care Med. 2019;34(11–12):990–5.

    PubMed  Google Scholar 

  43. Finger JR, Kurczewski LM, Brophy GM. Clevidipine versus nicardipine for acute blood pressure reduction in a neuroscience intensive care population. Neurocrit Care. 2017;26(2):167–73.

    CAS  PubMed  Google Scholar 

  44. Graffagnino C, Bergese S, Love J, Schneider D, Lazaridis C, LaPointe M, Lee K, Lynch G, Hu MY, Williams GC. Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial. Cerebrovasc Dis. 2013;36(3):173–80.

    CAS  PubMed  Google Scholar 

  45. Varelas PN, Abdelhak T, Corry JJ, James E, Rehman MF, Schultz L, Mays-Wilson K, Mitsias P. Clevidipine for acute hypertension in patients with subarachnoid hemorrhage: a pilot study. Int J Neurosci. 2014;124(3):192–8.

    CAS  PubMed  Google Scholar 

  46. Bettesworth JG, Martin DP, Tobias JD. Intraoperative use of clevidipine in a patient with von Hippel-Lindau disease with associated pheochromocytoma. J Cardiothorac Vasc Anesth. 2013;27(4):749–51.

    PubMed  Google Scholar 

  47. Luis-García C, Arbonés-Aran E, Teixell-Aleu C, Lorente-Poch L, Trillo-Urrutia L. Clevidipine for hypertension treatment in pheochromocytoma surgery. Rev Esp Anestesiol Reanim. 2018;65(4):225–8.

    Google Scholar 

  48. Meyer T, Tobias JD. Perioperative blood pressure management with clevidipine during coiling of cerebral artery aneurysms. Saudi J Anaesth. 2009;3(2):83–6.

    PubMed  PubMed Central  Google Scholar 

  49. Kako H, Gable A, Martin D, Beebe A, Thung A, Samora W, Klamar J, Bhalla T, Tobias JD. A prospective, open-label trial of clevidipine for controlled hypotension during posterior spinal fusion. J Pediatr Pharmacol Ther. 2015;20(1):54–60.

    PubMed  PubMed Central  Google Scholar 

  50. Tobias JD, Hoernschemeyer DG. Clevidipine for controlled hypotension during spinal surgery in adolescents. J Neurosurg Anesthesiol. 2011;23(4):347–51.

    PubMed  Google Scholar 

  51. Peacock F, Varon J, Ebrahimi R, Dunbar L, Pollack CV Jr. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis. Congest Heart Fail. 2010;16(2):55–9.

    CAS  PubMed  Google Scholar 

  52. Stoicea N, Joseph N, Bergese SD. Clevidipine-induced dyspnea relief in acute heart failure patients. EBioMedicine. 2016;10:23–4.

    PubMed  PubMed Central  Google Scholar 

  53. Dahl GP, Conner GE, Qiu F, Wang J, Spindler E, Campagna JA, Larsson HP. High affinity complexes of pannexin channels and L-type calcium channel splice-variants in human lung: possible role in clevidipine-induced dyspnea relief in acute heart failure. EBioMedicine. 2016;10:291–7.

    PubMed  PubMed Central  Google Scholar 

  54. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure—a Pilot Study (PRONTO). Am Heart J. 2014;167(4):529–36.

    CAS  PubMed  Google Scholar 

  55. Patel M, Meyer T, Tharakan A, Tobias JD. Intraoperative administration of clevidipine to prevent vasospasm after radial and internal mammary artery grafts during coronary artery bypass grafting. Am J Ther. 2012;19(3):e114–7.

    PubMed  Google Scholar 

  56. Kieler-Jensen N, Jolin-Mellgård A, Nordlander M, Ricksten SE. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 2000;44(2):186–93.

    CAS  PubMed  Google Scholar 

  57. Bailey JM, Lu W, Levy JH, Ramsay JG, Shore-Lesserson L, Prielipp RC, Brister NW, Roach GW, Jolin-Mellgard A, Nordlander M. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology. 2002;96(5):1086–94.

    CAS  PubMed  Google Scholar 

  58. Merry AF, Avery EG, Nussmeier NA, Playford HR, Warman GR, Wang Y, Sladen RN. Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study. Can J Anaesth. 2014;61(5):398–406.

    PubMed  Google Scholar 

  59. Peacock WF, Angeles JE, Soto KM, Lumb PD, Varon J. Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review. Ther Clin Risk Manag. 2009;5(3):627–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Tobias JD, Allee J, Ramachandran V, Groshong T. Clevidipine controls intraoperative blood pressure in an adolescent with renal failure. J Pediatr Pharmacol Ther. 2009;14(3):144–7.

    PubMed  PubMed Central  Google Scholar 

  61. Wang QD, Segawa D, Ericsson H, Sjöquist PO, Johansson L, Rydén L. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002;40(2):228–34.

    CAS  PubMed  Google Scholar 

  62. Gourine AV, Pernow J, Poputnikov DM, Sjöquist PO. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol. 2002;40(4):564–70.

    CAS  PubMed  Google Scholar 

  63. Segawa D, Sjöquist PO, Wang QD, Gonon A, Rydén L. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J Cardiovasc Pharmacol. 2002;40(3):339–45.

    CAS  PubMed  Google Scholar 

  64. Odenstedt J, Månsson C, Grip L. Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J Cardiovasc Pharmacol. 2004;44(4):407–15.

    CAS  PubMed  Google Scholar 

  65. Kaur H, Nattanamai P, Qualls KE. Propofol and clevidipine-induced hypertriglyceridemia. Cureus. 2018;10(8):e3165.

    PubMed  PubMed Central  Google Scholar 

  66. Short JH, Fatemi P, Ruoss S, Angelotti T. Clevidipine-induced extreme hypoxemia in a neurosurgical patient: a case report. A A Pract. 2020;14(2):60–2.

    PubMed  Google Scholar 

  67. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006;34(5):734–7.

    CAS  PubMed  Google Scholar 

  68. Wang X, Guo XY, Xu L, Liu B, Zhou LL, Wang XF, Wang D, Sun T. Studies on the competitive binding of cleviprex and flavonoids to plasma protein by multi-spectroscopic methods: a prediction of food-drug interaction. J Photochem Photobiol B. 2017;175:192–9.

    CAS  PubMed  Google Scholar 

  69. Towe E, Tobias JD. Preliminary experience with clevidipine in the pediatric population. J Intensive Care Med. 2010;25(6):349–52.

    PubMed  Google Scholar 

  70. Tobias JD, Tulman DB, Bergese SD. Clevidipine for perioperative blood pressure control in infants and children. Pharmaceuticals (Basel). 2013;6(1):70–84.

    CAS  Google Scholar 

  71. Tobias JD, Schechter WS, Phillips A, Weinstein S, Michler R, Berkenbosch JW, Montoya C. Clevidipine for perioperative blood pressure control in infants and children undergoing cardiac surgery for congenital heart disease. J Pediatr Pharmacol Ther. 2011;16(1):55–60.

    PubMed  PubMed Central  Google Scholar 

  72. Clevidipine. Drugs R D. 2002;3(3):190–2.

  73. Nordlander M, Sjöquist PO, Ericsson H, Rydén L. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004;22(3):227–50.

    CAS  PubMed  Google Scholar 

  74. Aronson S, Levy JH, Lumb PD, Fontes M, Wang Y, Crothers TA, Sulham KA, Navetta MS. Impact of perioperative blood pressure variability on health resource utilization after cardiac surgery: an analysis of the ECLIPSE trials. J Cardiothorac Vasc Anesth. 2014;28(3):579–85.

    PubMed  Google Scholar 

  75. The Medicines Company. Cleviprex (clevidipine) injectable emulsion for intravenous use: US prescribing information. 2011. http://www.cleviprex.com/. Accessed Mar 22, 2021

  76. Staff PDR, editor. Red book: pharmacy’s fundamental reference, 2008. Montvale: Thomson Healthcare; 2008.

    Google Scholar 

  77. Aronson S, Dasta JF, Levy JH, Lumb PD, Fontes M, Wang Y, Crothers TA, Sulham KA, Navetta MS. A cost analysis of the impact of a new intravenous antihypertensive in managing perioperative blood pressure during cardiac surgery. Hosp Pract (1995). 2014;42(3):26–32.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of South China, No. 28, Changsheng West Road, Zhengxiang District, Hengyang, 421001, Hunan, China

    Bo Xu, Zhen Chen & Gaorui Tang

Authors
  1. Bo Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaorui Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo Xu.

Ethics declarations

Funding

Not applicable.

Conflict of interest

All authors declared that they had no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not include any new research on humans or animals by any author.

Data Availability Statements

Not applicable.

Author Contribution

BX is responsible for document retrieval and article writing and inspection. ZC and GT are responsible for document retrieval and article inspection.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, B., Chen, Z. & Tang, G. The Current Role of Clevidipine in the Management of Hypertension. Am J Cardiovasc Drugs 22, 127–139 (2022). https://doi.org/10.1007/s40256-021-00494-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-021-00494-6

Search

Navigation